Key result
Percutaneous ASD and PFO closure is associated with 0% recurrent embolic events and residual shunts.
Why the study?
Short- and mid-term results of percutaneous closure of atrial septal defects and patent foramen ovale using various closure devices were evaluated.
Population
278 patients undergoing percutaneous closure of secundum ASD (n=134) or PFO (n=144)
Comparison
Percutaneous closure using Amplatzer, Occlutech Figulla, or BioSTAR devices
Design
Observational cohort study
Follow-up
Mean 35.1 ± 24.6 months for ASD cases, 24.9 ± 15.5 months for PFO cases
Authors
Loading...
Supports percutaneous ASD/PFO closure as a safe option; leaves open need for randomized trials to confirm efficacy.
Observational (n=278)
Percutaneous closure of secundum ASDs and PFOs using Amplatzer, Occlutech Figulla, and BioSTAR devices is an effective and safe treatment option with low complication rates.
Mehmet Ali Oto (2011) conducted an observational in Atrial septal defects (ASD) and patent foramen ovale (PFO) (n=278). Percutaneous closure using Amplatzer, Occlutech Figulla, or BioSTAR devices was evaluated on Recurrent embolic events (PFO) and residual shunts (ASD). Percutaneous closure of secundum ASDs and PFOs was safe and effective, with 0% recurrent embolic events after PFO closure and 0% residual shunts after ASD closure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: